Jill Clendening

Powers announces plan to step down from key diabetes leadership roles

Alvin C. Powers, MD, has announced plans to step down effective July 1, 2024, as director of the Vanderbilt Diabetes Center, director of the Vanderbilt Diabetes Research and Training Center, and chief of the Division of Diabetes, Endocrinology and Metabolism.

The research team includes, left to right, Bruno Scaglioni, PhD; Keith Obstein MD, MPH; James Martin, PhD; Claire Landewee, BS; Simone Calò, PhD; and Pietro Valdastri, PhD. (hoto by Susan Urmy)

VISE-affiliated researchers conduct phase 1 trial of novel magnetic endoscope for colonoscopies

A Vanderbilt research team is conducting the first phase 1 clinical trial of a magnetic, flexible endoscope that has the potential to provide a safer alternative to standard colonoscopy, particularly for individuals with inflammatory bowel disease.

Tirzepatide trial shows additional 21.1% weight loss following intensive lifestyle intervention

A Vanderbilt clinical trial evaluating the injectable prescription medication tirzepatide, showed an additional 21.1% weight loss after intensive lifestyle intervention in adults with obesity or who were overweight with weight-related comorbidities, excluding Type 2 diabetes.

Stevenson named chair of Department of Health Policy

David Stevenson has been named chair of the Department of Health Policy at Vanderbilt University Medical Center.

Sharon Kantanie, center, participated in the study of a drug that reduced soft-tissue flare-ups and the prevented new areas of abnormal bone formation. With her are, from left, Emily Shardelow, clinical/translational research coordinator; Sharon’s parents, Mary and Stan Kantanie; Margo Black, MSN, manager of research projects for Metabolic Bone Disorders; and Kathryn Dahir, MD, professor of Endocrinology and Diabetes. (photo by Erin O. Smith)

Drug trial shows reduced abnormal bone formation in those with fibrodysplasia ossificans progressiva

A Vanderbilt clinical trial evaluating the investigational drug garetosmab has shown that it reduced soft-tissue flare-ups significantly and prevented new areas of abnormal bone formation in patients with fibrodysplasia ossificans progressiva.

VUMC SMART Program Manager Christopher Brown, CC-P, center, teaching SMART rotators critical skills during February rotation. (Photo by Sfc. Justin Theodos)

New SMART rotation of military personnel takes place

The latest Strategic Medical Asset Readiness Training (SMART) rotation, which included 12 members of the United States military, recently came to Vanderbilt University Medical Center to work in clinical areas of the adult hospital.

1 7 8 9 10 11 35